Loading
LG
LHC Group, Inc Stock: price and insider trades · United States
LHC Group, Inc: what insiders have been doing
This page follows insider dealings at LHC Group, Inc as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. No insider at LHC Group, Inc has published a filing in the past twelve months. The most recent one dates from 22 February 2023.
Our records for LHC Group, Inc go back to 2016, with no purchases and 134 sales on the open market in total.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
403
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€119M
134 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$2B
Gross profitUS$760.8M39% margin
Net incomeUS$23.6M1.2% margin
Last declaration on 22 February 2023
Declarations403 total
1,554 shares@ US$170.0077.5% of flowCommon StockSEC:0001303313-23-000036:1
5,032 shares@ US$170.008.6% of flowCommon StockSEC:0001303313-23-000041:1
16 shares@ US$170.000.0% of flowCommon StockSEC:0001303313-23-000041:3
200,779 shares@ US$170.0016.3% of flowCommon StockSEC:0001303313-23-000037:1
604,013 shares@ US$170.0049.2% of flowCommon StockSEC:0001303313-23-000037:2
30,000 shares@ US$170.0020.8% of flowCommon StockSEC:0001303313-23-000048:1
27,848 shares@ US$170.0019.3% of flowCommon StockSEC:0001303313-23-000048:2
30,576 shares@ US$170.0056.4% of flowCommon StockSEC:0001303313-23-000040:1
45,937 shares@ US$170.0049.1% of flowCommon StockSEC:0001303313-23-000038:1
10,449 shares@ US$170.0080.9% of flowCommon StockSEC:0001303313-23-000043:1
1,830 shares@ US$170.003.1% of flowCommon StockSEC:0001303313-23-000041:2
4,041 shares0Common StockSEC:0001303313-23-000036:0
71,506 shares0Common StockSEC:0001303313-23-000038:0
30,357 shares0Common StockSEC:0001303313-23-000043:0
98,766 shares0Common StockSEC:0001303313-23-000037:0
4,372 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000040:0
30,500 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000047:0
7,700 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000044:0
27,100 shares@ US$170.0084.0% of flowCommon StockSEC:0001303313-23-000046:0
80,949 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000048:0
14,200 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000045:0
18,039 shares@ US$170.0099.7% of flowCommon StockSEC:0001303313-23-000042:0
50,578 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000041:0
12,023 shares@ US$170.00100.0% of flowCommon StockSEC:0001303313-23-000035:0
15,860 shares@ US$170.0095.5% of flowCommon StockSEC:0001303313-23-000039:0
25 of 403 declarations
About LHC Group, Inc
LHC Group, Inc. was a U.S.-based provider of post-acute and home-based healthcare services focused on delivering care where patients live. Founded in 1994 in Lafayette, Louisiana, the company began as a single home health agency and expanded over time through organic growth, partnerships, and acquisitions. Its headquarters were in Lafayette, Louisiana, United States. LHC Group traded on the NASDAQ market under the ticker LHCG before being acquired by UnitedHealth Group, with the transaction completed on February 22, 2023. For investors, that history remains relevant in the context of SEC filings, including Form 4 insider transaction reporting.
LHC Group’s business model was built around several service lines: home health, hospice, home- and community-based services, facility-based services through long-term acute care hospitals (LTACHs), and healthcare innovations. In practical terms, the company’s economic engine was centered on home-based care, post-discharge clinical follow-up, end-of-life support, and coordination services with hospitals and health systems. Management consistently emphasized a person-centered care approach designed to reduce avoidable readmissions, improve clinical outcomes, and support smoother transitions from acute care to the home setting.
Read moreShow less
From a competitive standpoint, LHC Group established itself as one of the better-known players in the U.S. home health and hospice landscape by combining scale, local market density, and hospital partnership capabilities. Prior to the acquisition, the company reported operating a broad national footprint across most states and the District of Columbia. Its investment case was based on a mix of geographic reach, clinical integration, and the ability to serve an aging population with increasingly complex care needs. The home health and hospice markets are highly fragmented, but they also face reimbursement pressure, regulatory oversight, and a clear industry shift toward value-based care.
Its core services included skilled nursing at home, therapy and rehabilitation, assistance with daily living, palliative and hospice care, and broader care-transition support. These offerings made LHC Group particularly relevant for patients recovering from hospitalization, managing chronic conditions, or requiring end-of-life care in a familiar environment.
A major recent development is that LHC Group is no longer an independent publicly traded company; it became part of UnitedHealth Group in 2023. That acquisition underscored the strategic value of home-based care assets within the broader U.S. healthcare ecosystem and Optum’s growth strategy. For French-speaking investors, LHC Group is best viewed as a former NASDAQ-listed specialist that helped accelerate consolidation in U.S. home health and hospice care, with a legacy that remains important even after its integration into a larger healthcare platform in the United States.
